The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESTRO 2025 | PLATO ACT 4: reducing radiotherapy dose in early-stage anal cancer maintains local RFS
Maria Antonietta Gambacorta, MD, Catholic University of the Sacred Heart, Milan, Italy, comments on the results of the PLATO ACT 4 randomized trial evaluating the reduced dose of chemotherapy in patients with early-stage anal cancer. Prof. Gambacorta notes that reducing the dose of radiotherapy from 50 Gray to 41 Gray in 23 fractions did not compromise the local recurrence-free survival rate, which remained above 85%. This interview took place at the ESTRO 2025 congress in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
